BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 07, 2005
 |  BioCentury  |  Finance

EPS watch

EPS watch

Company 3Q05 EPS est 3Q05EPS actual Outcome Growth from 3Q04 11/4cls Wk chg %chg Mcap chg 11/4mcap
Alkermes (ALKS) (A) -$0.11 $0.13 Beat by $0.24 NA $18.99 $3.11 20% $281.2 $1,716.9
The results for 2Q fiscal 06 compared to a $0.16 loss per share in 2Q of fiscal 05. In addition to blowing through the consensus EPS figures, ALKS beat the Street's revenue estimate of $31.5M for 2Q of fiscal 06. The company's revenes came in at $46.7M, up 159% vs. $18M in the same period last year. Schizophrenia drug Risperdal Consta from partner Johnson & Johnson (JNJ) was a big driver. ALKS recorded $13.6M in manufacturing revenue and $4M in...

Read the full 670 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >